SANTIAGO
MORENO GUILLÉN
Researcher to 2007
![Foto de Leopoldo](/img/nophoto.png)
Leopoldo
Muñoz Medina
Publications by the researcher in collaboration with Leopoldo Muñoz Medina (21)
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Journal of Biomedical Science, Vol. 28, Núm. 1
2020
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2018
-
Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status
Cells, Vol. 7, Núm. 11
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2014
-
Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions
PLoS ONE, Vol. 9, Núm. 12
-
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
AIDS, Vol. 28, Núm. 16, pp. 2461-2473
-
Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes
International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6
2009
-
Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality
Current HIV Research, Vol. 7, Núm. 2, pp. 224-230
2008
-
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status
International Journal of Tuberculosis and Lung Disease, Vol. 12, Núm. 12, pp. 1393-1400